MetGen

MetGen serves industries that utilize lignocellulosic biomass, including the pulp and paper, renewable chemicals, and biofuel sectors. Its business model involves creating customized enzymatic solutions tailored to specific client needs, moving away from a one-size-fits-all product offering. Revenue is generated through the sale of these enzyme solutions, technology licensing, and joint development projects. The company employs a flexible production strategy, using a network of European contract manufacturing partners to scale production, with plans for expansion into North America, South America, and Asia.

The company's flagship product portfolio, sold under the brand name MetZyme®, consists of highly active natural catalysts that accelerate chemical reactions. A key technological offering is the METNIN™ platform, which enables the enzymatic fractionation of lignin—a byproduct of pulp and biorefinery processes—into valuable 'drop-in' replacements for fossil-based chemicals like polyols and resins. This process allows clients to valorize waste streams and create higher-value biochemicals and biomaterials. MetGen's rapid development cycle, which can take an enzyme from concept to industrial scale in 6-9 months, provides a significant operational advantage.

MetGen has actively participated in collaborative research, leveraging public funding from programs like the EU's Horizon 2020 to advance its technology and build extensive value chains. The company has received numerous accolades, including being named in the Global Cleantech 100 list in 2013 and winning the Best in BioFuel / BioEnergy category at the GCCA Later Stage Awards in 2014.